- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Akebia Therapeutics' CEO on Mechanisms of HIF-PHI Candidate
Vadadustat is an investigational drug belonging to a class known as hypoxia-inducible prolyl hydroxylase inhibitors (HIF-PHIs) for the treatment of anemia in chronic kidney disease.
John Butler, CEO of Akebia Therapeutics, discusses the company's investigational drug candidate vadadustat, which belongs to a new class of drugs called hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI). The class works by restoring production of the hormone erythropoietin and improving iron regulation in patients with chronic kidney disease who are anemic.
Transcript:
Can you discuss vadadustat as an HIF-PH inhibitor and how this class of drugs works?
So vadadustat is a HIF-PHI, which is a hypoxia-inducible prolyl hydroxylase inhibitor and basically, its mechanism of action is the same as increasing altitude. When we go up in altitude, our body stabilizes hypoxia inducible factor, our body recognizes that the oxygen level is low, and it stabilizes HIF. And it does this by inhibiting the enzymes that normally inhibit HIF. So vadadustat basically works by inhibiting the inhibitor, inhibiting the pro hydroxylase which allows HIF to stabilize, which allows the body to make red blood cells. So it's a very physiologic process by which vadadustat works.
Study Finds Obesity May Worsen Multiple Sclerosis: Genetic Analysis Points to Causal Link
November 21st 2024A new study aimed at exploring the relationship between obesity and multiple sclerosis severity using genetic data finds that higher BMI and other obesity measures were associated with increased disability progression in patients with MS.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
Semaglutide Eligibility Expands to Over Half of US Adults
November 21st 2024Over half of the US adult population may benefit from semaglutide, a drug primarily used for weight loss and diabetes, although concerns about access and cost persist, especially considering its potential for wider health applications.
Read More
Higher Life’s Essential 8 Scores Associated With Reduced COPD Risk
November 21st 2024Higher Life’s Essential 8 (LE8) scores, especially those reflecting lower nicotine exposure and better sleep health, are inversely associated with chronic obstructive pulmonary disease (COPD) risk, emphasizing the importance of cardiovascular health (CVH) in disease prevention.
Read More
